Which patients with intermediate and high risk prostate cancer should not receive androgen deprivation therapy?

Based on randomized trials that didn't exclude patients with cardiac risk factors, an overall survival benefit has been observed for intermediate and high risk localized prostate cancer. Review of RTOG studies has not detected an increase in cardiovascular events. That said, appropriate management o...

For men with intermediate risk disease, the jury’s still out pending RTOG 0815 as to which men will benefit most from ADT. Retrospective data suggest that a ‘favorable’ intermediate risk group can be identified, that behave similarly to low risk disease and hence may not benefit as much from A...